Gerostate Alpha, with a $15 million valuation cap, is raising funds on Wefunder. The pharmaceutical company is making drugs that slow down tissue aging. The unbiased drug development pipeline of the company addresses multiple functional domains of aging, including cardiovascular, muscular, neurological, and metabolic. Simon Melov founded Gerostate Alpha in June 2018. The proceeds of the current crowdfunding round, with a minimum target of $50,000 and a maximum target of $1,070,000, will be used towards the eight-month study of three priority candidate compounds, personnel and equipment costs, animal purchase and housing, equipment, and animal feed and reagents. Gerostate Alpha delivers drug candidates to slow aging with a success rate of 20%. The company is currently testing its products on aging mice.